These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 15878631)

  • 21. Advances in the treatment of lung cancer: economic and organizational aspects.
    Mantini G; Trodella L; Balducci M; Turriziani A; Loffreda M; Manfrida S
    Rays; 1999; 24(3):428-34. PubMed ID: 10605303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of the JACIE standards for a haematopoietic progenitor cell transplantation programme: a cost analysis.
    Zahnd D; Leibundgut K; Zenhäusern R; Pabst T; Fontana S; Schneider R; Tobler A; Zwicky C
    Bone Marrow Transplant; 2004 Nov; 34(10):847-53. PubMed ID: 15517005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity-based costing: a practical model for cost calculation in radiotherapy.
    Lievens Y; van den Bogaert W; Kesteloot K
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):522-35. PubMed ID: 12957266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the benefit and cost of radiotherapy for lung cancer.
    Barbera L; Walker H; Foroudi F; Tyldesley S; Mackillop W
    Int J Technol Assess Health Care; 2004; 20(4):545-51. PubMed ID: 15609808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Merits of multidisciplinary treatment in lung cancer].
    Kawahara M
    Nihon Rinsho; 2002 May; 60 Suppl 5():433-7. PubMed ID: 12101708
    [No Abstract]   [Full Text] [Related]  

  • 26. Radiotherapy cost-calculation and its impact on capacity planning.
    Lievens Y; Slotman BJ
    Expert Rev Pharmacoecon Outcomes Res; 2003 Aug; 3(4):497-507. PubMed ID: 19807460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiobiologically based assessments of the net costs of fractionated radiotherapy.
    Dale RG; Jones B
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):739-46. PubMed ID: 8948360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the cost of radiotherapy for 5-year local control and overall survival benefit.
    Batumalai V; Wong K; Shafiq J; Hanna TP; Gabriel G; Heberle J; Koprivic I; Kaadan N; King O; Tran T; Cassapi L; Forstner D; Delaney GP; Barton M
    Radiother Oncol; 2019 Jul; 136():154-160. PubMed ID: 31015119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Economic evaluation of the treatment of patients with early-stage lung cancer].
    Vagner RI; Komiakov IP; Blinov NN; Lemekhov VG
    Sov Med; 1986; (12):89-91. PubMed ID: 3563709
    [No Abstract]   [Full Text] [Related]  

  • 30. Economic evaluation and quality of life assessments in cancer clinical trials: the CHART Trial.
    Morris J; Goddard M
    Eur J Cancer; 1993; 29A(5):766-70. PubMed ID: 8471337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic-statistical design of synthetic np chart with estimated process parameter.
    Lee MH; Khoo MBC; Chew X; Then PHH
    PLoS One; 2020; 15(4):e0230994. PubMed ID: 32267874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost effectiveness of a radiation therapy simulator: a model for the determination of need.
    Dritschilo A; Sherman D; Emami B; Piro AJ; Hellman S
    Int J Radiat Oncol Biol Phys; 1979 Feb; 5(2):243-7. PubMed ID: 110738
    [No Abstract]   [Full Text] [Related]  

  • 33. The economics of lung cancer.
    Boyer M
    Lung Cancer; 1996 Feb; 14(1):13-7. PubMed ID: 8696716
    [No Abstract]   [Full Text] [Related]  

  • 34. Radiotherapy for Cancer. Summary.
    Acta Oncol; 1996; 35 Suppl 6():9-23. PubMed ID: 9181762
    [No Abstract]   [Full Text] [Related]  

  • 35. Economic statistical model of the np chart for monitoring defectives.
    Haridy S; Alamassi B; Maged A; Shamsuzzaman M; Al Owad A; Bashir H
    Sci Rep; 2023 Aug; 13(1):13179. PubMed ID: 37580471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective Chart Review Studies: Strategies To Ensure Robust Data Quality.
    Stein D; Bassel M; Payne KA
    Value Health; 2014 Nov; 17(7):A583. PubMed ID: 27201973
    [No Abstract]   [Full Text] [Related]  

  • 37. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Chang JY; Jabbour SK; De Ruysscher D; Schild SE; Simone CB; Rengan R; Feigenberg S; Khan AJ; Choi NC; Bradley JD; Zhu XR; Lomax AJ; Hoppe BS;
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):505-516. PubMed ID: 27084663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economics of treatments for non-small cell lung cancer.
    Chouaid C; Atsou K; Hejblum G; Vergnenegre A
    Pharmacoeconomics; 2009; 27(2):113-25. PubMed ID: 19254045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CHART in lung cancer: economic evaluation and incentives for implementation.
    Lievens Y; Kesteloot K; Van den Bogaert W
    Radiother Oncol; 2005 May; 75(2):171-8. PubMed ID: 15878631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic consequence of local control with radiotherapy: cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer.
    Lievens Y; Kesteloot K; van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1122-31. PubMed ID: 16253774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.